NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk

News · Targeted Oncology · 2026-11-12. Number 2 in the UrologyWatch Top 5 for November 16, 2026.

NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.

Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.

Source: Targeted Oncology

The full November 16, 2026 edition · Today's urology news

Loading today's edition…